Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer

Surgical Oncology

Volumn 18, Issue 3, 2009, Pages 275-282

  Shaw, G ^a   Oliver, R T D ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Androgen ablation; Androgen suppression; Hormone therapy; Intermittent; Prostate cancer; Quality of life

Indexed keywords

ANTIANDROGEN; DIETHYLSTILBESTROL; GONADORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

CANCER HORMONE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; FOLLOW UP; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MICE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 68849111294     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2009.02.003     Document Type: Review

References (55)

1. Berruti A., Tucci M., Terrone C., Gorzegno G., Scarpa R.M., Angeli A., et al. Background to and management of treatment-related bone loss in prostate cancer 10. Drugs Aging 19 12 (2002) 899-910
2. Salminen E.K., Portin R.I., Koskinen A., Helenius H., and Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients 96. Clin Cancer Res 10 22 (2004) 7575-7582
3. Klotz L.H., Herr H.W., Morse M.J., and Whitmore Jr. W.F. Intermittent endocrine therapy for advanced prostate cancer 33. Cancer 58 11 (1986) 2546-2550
4. Noble R.L. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 37 1 (1977) 82-94
5. Bruchovsky N., Rennie P.S., Coldman A.J., Goldenberg S.L., To M., and Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma 54. Cancer Res 50 8 (1990) 2275-2282
6. Sato N., Gleave M.E., Bruchovsky N., Rennie P.S., Goldenberg S.L., Lange P.H., et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model 20. J Steroid Biochem Mol Biol 58 2 (1996) 139-146
7. Byar D.P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 5 (1973) 1126-1130
8. Jordan Jr. W.P., Blackard C.E., and Byar D.P. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70 12 (1977) 1411-1413
9. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 24 (1999 Dec 9) 1781-1788
10. The Medical Research Council Prostate Cancer Working Party Investigators, G., immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. BJU Int 136 (1997) 235
11. Studer U.E., Whelan P., Albrecht W., Casselman J., de Reijke T., Hauri D., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 12 (2006 Apr 20) 1868-1876
12. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., and Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen 21. Cancer 71 9 (1993) 2782-2790
13. Sato N., Sadar M.D., Bruchovsky N., Saatcioglu F., Rennie P.S., Sato S., et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP 66. J Biol Chem 272 28 (1997) 17485-17494
14. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer 34. N Engl J Med 332 21 (1995) 1393-1398
15. Craft N., Shostak Y., Carey M., and Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 3 (1999) 280-285
16. Raffo A.J., Perlman H., Chen M.W., Day M.L., Streitman J.S., and Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55 19 (1995) 4438-4445
17. Buhler K.R., Santucci R.A., Royai R.A., Whitney S.C., Vessella R.L., Lange P.H., et al. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model 24. Prostate 43 1 (2000) 63-70
18. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 15 (2004) 1502-1512
19. Shamash J., Dancey G., Barlow C., Wilson P., Ansell W., and Oliver R.T. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 92 1 (2005) 36-40
20. Shamash J., Davies A., Ansell W., McFaul S., Wilson P., Oliver T., et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 98 1 (2008) 22-24
21. Albrecht W., Collette L., Fava C., Kariakine O.B., Whelan P., Studer U.E., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study 5. Eur Urol 44 5 (2003) 505-511
22. Grossfeld G.D., Small E.J., and Carroll P.R. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology 51 1 (1998) 137-144
23. De La Taille A., Zerbib M., Conquy S., Amsellem-Ouazana D., Thiounn N., Flam T.A., et al. Intermittent androgen suppression in patients with prostate cancer 39. BJU Int 91 1 (2003) 18-22
24. Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D., and Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report 30. Urology 45 5 (1995) 839-844
25. Lane T.M., Ansell W., Farrugia D., Wilson P., Williams G., Chinegwundoh F., et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression 35. Urol Int 73 2 (2004) 117-122
26. Malone S., Perry G., Segal R., Dahrouge S., and Crook J. Long-term side-effects of intermittent androgen suppression therapy in prostate cancer: results of a phase II study 134. BJU Int 96 4 (2005) 514-520
27. Prapotnich D., Fizazi K., Escudier B., Mombet A., Cathala N., and Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer 43. Eur Urol 43 3 (2003) 233-239
28. Spry N.A., Kristjanson L., Hooton B., Hayden L., Neerhut G., Gurney H., et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 42 8 (2006) 1083-1092
29. Strum S.B., Scholz M.C., and McDermed J.E. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist 5 1 (2000) 45-52
30. Youssef E., Tekyi-Mensah S., Hart K., Bolton S., and Forman J. Intermittent androgen deprivation for patients with recurrent/metastatic prostate cancer 7. Am J Clin Oncol 26 5 (2003) e119-e123
31. Shaw G., Purkiss T., Oliver R.T., and Prowse D.M. Re: Christine McKillop. Interview with Jack Schalken: PCA3 and its use as a diagnostic test in prostate cancer. Eur Urol 50 (2006) 153-154 Eur Urol. 2007 Mar;51(3):860-2
32. Shaw G.L., Wilson P., Cuzick J., Prowse D.M., Goldenberg S.L., Spry N.A., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99 5 (2007) 1056-1065
33. Peyromaure M., Delongchamps N.B., Debre B., and Zerbib M. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience 106. Urology 65 4 (2005) 724-729
34. Gillatt D. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?. J Cancer Res Clin Oncol 132 Suppl. 1 (2006 Aug) S17-S26 [Review]
35. Iversen P., and Roder M.A. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther 8 3 (2008) 361-369
36. Conti P.D., Atallah A.N., Arruda H., Soares B.G., El Dib R.P., and Wilt T.J. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 4 (2007) CD005009
37. Calais Da Silva F. SEUG Intermittent Hormone Therapy Trial 9901. Unpublished data, personal communication; 2005.
38. Calais Da Silva F., and Bono A. Phase III study of Intermittent MAB versus continuous MAB. International co-operative study (abstract). Whelan P, Brausi M, Queimadelos M, Portilho J. Kirkali Z. J Urol 173 (4) supp (2005) 309
39. Tunn U. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. BJU Int 99 Suppl. 1 (2007) 19-22 [discussion 23-4]
40. de Leval J., Boca P., Yousef E., Nicolas H., Jeukenne M., Seidel L., et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial 107. Clin Prostate Cancer 1 3 (2002) 163-171
41. Boccon-Gibod L., Hammerer P., Madersbacher S., Mottet N., Prayer-Galetti T., and Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 100 4 (2007) 738-743
42. Hussain M., Tangen C.M., Higano C., Schelhammer P.F., Faulkner J., Crawford E.D., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24 24 (2006 Aug 20) 3984-3990
43. Pettersson B., Varenhorst E., Petas A., and Sandow J. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Eur Urol 50 3 (2006 Sep) 483-489
44. Gulley J.L., Figg W.D., Steinberg S.M., Carter J., Sartor O., Higano C.S., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy 133. J Urol 173 5 (2005) 1567-1571
45. Andriole G.L., Humphrey P., Ray P., Gleave M.E., Trachtenberg J., Thomas L.N., et al. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 172 3 (2004 Sep) 915-919
46. Thompson I.M., Klein E.A., Lippman S.M., Coltman C.A., and Djavan B. Prevention of prostate cancer with finasteride: US/European perspective 72. Eur Urol 44 6 (2003) 650-655
47. Handel L.N., Agarwal S., Schiff S.F., Kelty P.J., and Cohen S.I. Can effect of finasteride on prostate-specific antigen be used to decrease repeat prostate biopsy?. Urology 68 6 (2006 Dec) 1220-1223
48. Eggener S.E., Stern J.A., Jain P.M., Oram S., Ai J., Cai X., et al. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 66 5 (2006 April 1) 495-502
49. Scholz M.C., Jennrich R.I., Strum S.B., Johnson H.J., Guess B.W., and Lam R.Y. Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. J Urol 175 5 (2006 May) 1673-1678
50. Bhandari M.S., Crook J., and Hussain M. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 32 (2005) 8212-8218
51. http://www.nice.org.uk/guidance/.
52. Schatzl G., Madersbacher S., Thurridl T., Waldmuller J., Kramer G., Haitel A., et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47 1 (2001) 52-58
53. Wafa L.A., Palmer J., Fazli L., Hurtado-Coll A., Bell R.H., Nelson C.C., et al. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 38 1 (2007) 161-170
54. Gleave M., Qian J., Andreou C., Pommerville P., Chin J., Casey R., et al. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer-results from a 4-month pre-radical prostatectomy study. Prostate 66 15 (2006) 1674-1685
55. Van Poppel H., Ameye F., Oyen R., Van D.V., and Baert L. Neo-adjuvant hormonotherapy does not facilitate radical prostatectomy. Acta Urol Belg 60 3 (1992) 73-82